Gamma-delta T-cell receptor constant region (TRGC/TRDC)

The gamma-delta T-cell receptor (TCR) constant region is a structural component of the TCR heterodimer found on gamma-delta T cells, a distinct subset of lymphocytes that bridge innate and adaptive immunity (UniProt: P03986, P0CF51). Unlike alpha-beta T cells, gamma-delta T cells recognize antigens in a non-MHC-restricted manner, often responding to phosphoantigens or stress-induced molecules (PubMed: 32060401). The constant regions, encoded by the TRGC and TRDC genes, provide structural stability to the receptor complex and are essential for signal transduction through the CD3 complex. In therapeutic development, the gamma-delta TCR constant region is a key target for bispecific antibodies and cell therapies designed to selectively activate and redirect these potent cytotoxic cells against tumor cells (PubMed: 31515558). This targeting strategy is particularly attractive because gamma-delta T cells possess natural anti-tumor properties and do not cause graft-versus-host disease (GvHD), making them ideal for allogeneic "off-the-shelf" therapies. Current drug candidates, such as bispecific gamma-delta T-cell engagers (GADEs) like LAVA-1207, utilize the TCR complex to bridge T cells with tumor-associated antigens (LAVA Therapeutics, 2023). These therapies are being investigated for both hematological malignancies and solid tumors, where they aim to enhance immune infiltration and overcome the immunosuppressive tumor microenvironment.

Other names

T-cell receptor gamma constantT-cell receptor delta constantTRGC1TRGC2TRDCTCR gamma/delta constant regionTCRGTCRD

Bispecific T-cell engagement, TCR-mediated activation, and redirection of gamma-delta T-cells to tumor cells via the TCR complex.